

Mattia Bonsignori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8604601/publications.pdf>

Version: 2024-02-01

82
papers

8,747
citations

57631

44
h-index

60497

81
g-index

93
all docs

93
docs citations

93
times ranked

6308
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. <i>Nature</i> , 2011, 480, 336-343.	13.7	794
2	Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. <i>Science</i> , 2011, 333, 1593-1602.	6.0	788
3	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. <i>Journal of Virology</i> , 2011, 85, 9998-10009.	1.5	393
4	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. <i>Immunity</i> , 2013, 38, 176-186.	6.6	374
5	Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9019-9024.	3.3	371
6	Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. <i>Journal of Virology</i> , 2012, 86, 11521-11532.	1.5	357
7	Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies. <i>Immunity</i> , 2013, 39, 245-258.	6.6	332
8	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016, 165, 449-463.	13.5	305
9	Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. <i>Journal of Infectious Diseases</i> , 2012, 206, 431-441.	1.9	273
10	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. <i>Cell</i> , 2014, 158, 481-491.	13.5	266
11	Interaction with Cellular CD4 Exposes HIV-1 Envelope Epitopes Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity. <i>Journal of Virology</i> , 2014, 88, 2633-2644.	1.5	237
12	A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. <i>Nature Medicine</i> , 2018, 24, 408-416.	15.2	235
13	Staged induction of HIV-1 glycanâ€“dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	212
14	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. <i>Journal of Virology</i> , 2014, 88, 7715-7726.	1.5	169
15	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 81-90.	3.6	162
16	Antibodyâ€“virus coâ€“evolution in <scp>HIV</scp> infection: paths for <scp>HIV</scp> vaccine development. <i>Immunological Reviews</i> , 2017, 275, 145-160.	2.8	160
17	Early Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape. <i>PLoS Pathogens</i> , 2012, 8, e1002721.	2.1	159
18	Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design. <i>Journal of Virology</i> , 2012, 86, 4688-4692.	1.5	159

#	ARTICLE	IF	CITATIONS
19	Polyreactivity and Autoreactivity among HIV-1 Antibodies. <i>Journal of Virology</i> , 2015, 89, 784-798.	1.5	154
20	Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. <i>Journal of Clinical Investigation</i> , 2015, 125, 4077-4090.	3.9	124
21	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , 2019, 25, 59-72.e8.	5.1	124
22	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017, 2, .	5.6	119
23	Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. <i>Science</i> , 2019, 366, .	6.0	118
24	Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. <i>Cell Host and Microbe</i> , 2018, 23, 759-765.e6.	5.1	98
25	Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion. <i>Journal of Virology</i> , 2013, 87, 1554-1568.	1.5	97
26	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. <i>Cell Reports</i> , 2017, 21, 3681-3690.	2.9	97
27	An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. <i>Journal of Clinical Investigation</i> , 2014, 124, 1835-1843.	3.9	93
28	Antibody Feedback Limits the Expansion of B Cell Responses to Malaria Vaccination but Drives Diversification of the Humoral Response. <i>Cell Host and Microbe</i> , 2020, 28, 572-585.e7.	5.1	87
29	Epitope Specificity of Human Immunodeficiency Virus-1 Antibody Dependent Cellular Cytotoxicity [ADCC] Responses. <i>Current HIV Research</i> , 2013, 11, 378-387.	0.2	82
30	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	81
31	A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing Antibodies. <i>Journal of Virology</i> , 2012, 86, 8319-8323.	1.5	76
32	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. <i>Nature Communications</i> , 2017, 8, 1732.	5.8	76
33	Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 18214-18219.	3.3	73
34	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. <i>Cell Reports</i> , 2017, 18, 2175-2188.	2.9	69
35	Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. <i>Nature Immunology</i> , 2020, 21, 199-209.	7.0	68
36	HIV-1 Envelope Induces Memory B Cell Responses That Correlate with Plasma Antibody Levels after Envelope gp120 Protein Vaccination or HIV-1 Infection. <i>Journal of Immunology</i> , 2009, 183, 2708-2717.	0.4	67

#	ARTICLE	IF	CITATIONS
37	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	5.1	66
38	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. <i>Immunity</i> , 2014, 41, 909-918.	6.6	65
39	Progress in HIV-1 vaccine development. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 3-10.	1.5	62
40	Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses. <i>Journal of Virological Methods</i> , 2014, 208, 107-114.	1.0	62
41	HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. <i>Trends in Microbiology</i> , 2012, 20, 532-539.	3.5	61
42	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. <i>Immunity</i> , 2018, 49, 1162-1174.e8.	6.6	61
43	Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees. <i>Journal of Virology</i> , 2013, 87, 7828-7836.	1.5	59
44	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. <i>Cell</i> , 2021, 184, 2955-2972.e25.	13.5	57
45	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008026.	2.1	56
46	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. <i>Journal of Virology</i> , 2017, 91, .	1.5	52
47	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , 2021, 371, .	6.0	49
48	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , 2018, 92, .	1.5	45
49	Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8614-8619.	3.3	42
50	Capacity for Infectious HIV-1 Virion Capture Differs by Envelope Antibody Specificity. <i>Journal of Virology</i> , 2014, 88, 5165-5170.	1.5	41
51	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. <i>Nature Communications</i> , 2019, 10, 2898.	5.8	35
52	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. <i>EBioMedicine</i> , 2016, 12, 196-207.	2.7	34
53	Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. <i>Nature Communications</i> , 2019, 10, 654.	5.8	34
54	Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. <i>Vaccine</i> , 2005, 23, 5306-5320.	1.7	33

#	ARTICLE	IF	CITATIONS
55	Prevalence and characterization of metallo- β -lactamases in clinical isolates of pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease, 2004, 48, 131-135.	0.8	31
56	HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope. Nature Communications, 2018, 9, 1111.	5.8	30
57	Immune checkpoint modulation enhances HIV-1 antibody induction. Nature Communications, 2020, 11, 948.	5.8	27
58	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. Viruses, 2015, 7, 5443-5475.	1.5	26
59	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. Communications Biology, 2018, 1, 134.	2.0	26
60	mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Reports, 2022, 38, 110514.	2.9	23
61	HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail. Frontiers in Bioscience - Landmark, 2008, 13, 609.	3.0	22
62	HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. JCI Insight, 2020, 5, .	2.3	18
63	Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. Journal of Virology, 2014, 88, 9406-9417.	1.5	16
64	Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. JCI Insight, 2018, 3, .	2.3	16
65	HIV Vaccine Rationale, Design and Testing. Current HIV Research, 2005, 3, 107-112.	0.2	13
66	Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. EBioMedicine, 2015, 2, 713-722.	2.7	13
67	HIV vaccines: brief review and discussion of future directions. Expert Review of Vaccines, 2005, 4, 305-313.	2.0	11
68	Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. JCI Insight, 2016, 1, e88522.	2.3	10
69	Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations. Cell Reports, 2021, 36, 109561.	2.9	9
70	Will studies in individuals with systemic lupus erythematosus be the key to future HIV vaccine design?. Expert Review of Vaccines, 2014, 13, 1271-1273.	2.0	6
71	Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial. MBio, 2020, 11, .	1.8	6
72	Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary?. AIDS Research and Therapy, 2005, 2, 3.	0.7	5

#	ARTICLE	IF	CITATIONS
73	Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome. <i>Viral Immunology</i> , 2018, 31, 124-132.	0.6	4
74	A Multi-Vector, Multi-Envelope HIV-1 Vaccine. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2007, 12, 68-76.	0.3	3
75	Simultaneous Detection of Antigen-Specific IgG- and IgM-Secreting Cells with a B Cell Fluorospot Assay. <i>Cells</i> , 2012, 1, 15-26.	1.8	2
76	Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. <i>Journal of Virological Methods</i> , 2017, 249, 85-93.	1.0	2
77	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. <i>PLoS Pathogens</i> , 2021, 17, e1009624.	2.1	2
78	A combination of 5-fluorouracil and membrane-bound antibody inhibits B-cell lymphoma growth in a mouse model system. <i>Leukemia and Lymphoma</i> , 2007, 48, 406-409.	0.6	1
79	ÅÅÅÅRapid Selection of HIV Envelopes that Bind to Neutralizing Antibody B Cell Lineage Members with Functional Improbable Mutations. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
80	P04-01. Simultaneous enumeration of HIV-1 gp41 Env-specific IgG and IgM antibody-secreting cells with a multiplex B-cell fluorospot assay. <i>Retrovirology</i> , 2009, 6, .	0.9	0
81	P04-48. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after gp120 protein vaccination or chronic HIV-1 infection. <i>Retrovirology</i> , 2009, 6, .	0.9	0
82	116â€fAutologous and Heterologous Neutralizing Antibody Responses in HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 47.	0.9	0